Abstract: Population aging and unhealthy lifestyle have increased the incidence of coronary heart disease (CHD). Percutaneous coronary intervention (PCI) has become one of the main revascularization treatments for CHD and is widely used clinically. However, the incidence of PCI-related myocardial infarction (PMI) has increased year by year and PMI has become a hot research spot of coronary intervention treatment. Cardiac troponin I (cTnI) is the most sensitive biochemical maker of myocardial injury and is more and more used in PMI treatment. This article reviews the results of recent clinical studies on cTnI in PMI treatment.